Abstract:Background Lung cancer has the highest cancer-related mortality worldwide. Lung adenocarcinoma (LUAD) is the most common histological subtype of non-small cell lung cancer (NSCLC). Chromatin licensing and DNA replication factor 1 (CDT1), a key regulator of cell cycle control and replication in eukaryotic cells, has been implicated in various cancer-related processes. Given its significant role in cancer, the focus on CDT1 in this study is justified as it holds promise as a potential biomarker or therapeutic target for cancer treatment. However, its prognostic value in lung adenocarcinoma (LUAD) remains unclear. Methods Bioinformatics analysis was conducted using data obtained from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) databases were utilized to predict biological processes and signaling pathways, respectively. The LinkedOmics database was employed to identify differentially expressed genes (DEGs) associated with CDT1. Nomograms and Kaplan-Meier plots were generated to assess the survival rates of patients with lung adenocarcinoma (LUAD). To determine the RNA and protein expression levels of CDT1 in LUAD and adjacent normal tissues, quantitative polymerase chain reaction (qPCR) and immunohistochemistry techniques were employed, respectively. Results CDT1 was upregulated in the vast majority of cancer tissues, based on pan-cancer analysis in TCGA and GEO datasets, as to lung cancer, the level of CDT1 expression was much higher in LUAD tissue than in healthy lung tissue. Our clinical data supported these findings. In our study, we used a specific cutoff value to dichotomize the patient samples into high and low CDT1 expression groups. The Kaplan–Meier survival curve revealed poor survival rates in CDT1 high expression group than the low expression group. To determine if CDT1 expression was an independent risk factor in LUAD patients, univariate and multivariate Cox regression analyses were performed. The result showed that CDT1 was a potential novel prognosis factor for LUAD patients, whose prognosis was poorer when CDT1 expression was higher. Based on functional enrichment analysis, highly expressed DEGs of CDT1-high patients were predicted to be involved in the cell cycle. According to our analysis of immune infiltration, CDT1 exhibited a strong correlation with specific immune cell subsets and was found to be a significant predictor of poor survival in patients with LUAD. Conclusions Our research found that CDT1 was upregulated in LUAD and that high CDT1 expression predicted poor prognosis. We comprehensively and systematically analyzed the expression level in the datasets as well as in our own clinical samples, we also evaluated the prognostic and diagnostic value of CDT1, and finally, the potential mechanisms of CDT1 in the progression of LUAD. These results suggested that CDT1 may be a prognostic marker and therapeutic target for LUAD.

CDT1, transcriptionally regulated by E2F2, promotes lung adenocarcinoma progression

E2F1 Promotes Cell Cycle Progression by Stabilizing Spindle Fiber in Colorectal Cancer Cells

MTHFD2 Promotes Tumorigenesis and Metastasis in Lung Adenocarcinoma by Regulating AKT/GSK‐3β/β‐catenin Signalling

MCTS1 Promotes the Development of Lung Adenocarcinoma by Regulating E2F1 Expression

Identification of CDT1 as a prognostic marker in human lung adenocarcinoma using bioinformatics approaches

Meiotic nuclear divisions 1 (MND1) fuels cell cycle progression by activating a KLF6/E2F1 positive feedback loop in lung adenocarcinoma

DDX18 Facilitates the Tumorigenesis of Lung Adenocarcinoma by Promoting Cell Cycle Progression through the Upregulation of CDK4

[Role of Eukaryotic Translation Elongation Factor 1 Family Members in the Tumorigenesis and Progression of Lung Adenocarcinoma].

Oncogenic Role of Epithelial Cell Transforming Sequence 2 in Lung Adenocarcinoma Cells.

A Novel Lncrna, LUADT1, Promotes Lung Adenocarcinoma Proliferation Via the Epigenetic Suppression of P27

CXXC finger protein 1 (CFP1) bridges the reshaping of genomic H3K4me3 signature to the advancement of lung adenocarcinoma

Knockdown of GTF2E2 Inhibits the Growth and Progression of Lung Adenocarcinoma Via RPS4X in Vitro and in Vivo

CDCA gene family promotes progression and prognosis in lung adenocarcinoma

High ECT2 Expression is an Independent Prognostic Factor for Poor Overall Survival and Recurrence-Free Survival in Non-Small Cell Lung Adenocarcinoma

EIF3H Interacts with PDCD4 Enhancing Lung Adenocarcinoma Cell Metastasis.

Retracted: Oncogenic Role Of Epithelial Cell Transforming Sequence 2 In Lung Adenocarcinoma Cells (Retracted Article. See Vol. 22, 2021)

Integrated analysis of the E2F transcription factors across cancer types

TCTP Promotes Epithelial-Mesenchymal Transition in Lung Adenocarcinoma.

Transcriptional E2F1/2/5/8 As Potential Targets and Transcriptional E2F3/6/7 As New Biomarkers for the Prognosis of Human Lung Carcinoma

ETV4 mediated lncRNA C2CD4D-AS1 overexpression contributes to the malignant phenotype of lung adenocarcinoma cells via miR-3681-3p/NEK2 axis

Molecular Mechanism of Cyclin E1 in Lung Adenocarcinoma and Their Cellular Response